Whooping cough due to Bordetella parapertussis: An unresolved problem

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 3, 2004, Pages 447-454

  Watanabe, Mineo ^a   Nagai, Masaaki ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b KITASATO INSTITUTE   (Japan)

Author keywords

Acellular pertussis vaccine; Bordetella parapertusis; Bordetella pertusis; Epidemiology; Filamentous hemagglutinin; Fimbriae; Pediatrics; Pertactin; Pertussis toxin; Respiratory infection; Whole cell pertussis vaccine; Whooping cough

Indexed keywords

ACELLULAR VACCINE; PERTUSSIS VACCINE; VIRULENCE FACTOR;

BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; CLINICAL FEATURE; CLINICAL RESEARCH; COMMON COLD; COUGHING; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG EFFICACY; ENCEPHALITIS; HUMAN; NONHUMAN; PERTUSSIS; PNEUMONIA; REVIEW; SEROLOGY; SYMPTOMATOLOGY; VACCINATION; VOMITING;

EID: 2942550802     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.3.447     Document Type: Review

References (51)

1. Locht C. Molecular aspects of Bordetella pertussis pathogenesis. Int. Microbiol. 2(3), 137-144 (1999).
2. Parton R. Review of the biology of Bordetella pertussis. Biologicals 27(2), 71-76 (1999).
3. Kerr JR, Preston NW. Current pharmacotherapy of pertussis. Expert Opin. Pharmacother. 2(8), 1275-1282 (2001).
4. Heininger U, Stehr K, Schmitt-Grohe S et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr. Infect. Dis. J. 13(4), 306-309 (1994).
5. Liese JG, Renner C, Stojanov S, Belohradsky BH. Clinical and epidemiological picture of B. pertussis and B. parapertussis infections after introduction of acellular pertussis vaccines. Arch. Dis. Child. 88(8), 684-687 (2003).
6. Mills KH. Immunity to Bordetella pertussis. Microbes Infect. 3(8), 655-677 (2001).
7. Chen W, Alley MR, Manktelow BW, Hopcroft D, Bennett R. Pneumonia in lambs inoculated with Bordetella parapertussis: bronchoalveolar lavage and ultrastructural studies. Vet. Pathol. 25(4), 297-303 (1988).
8. Porter JF, Connor K, Donachie W. Isolation and characterization of Bordetella parapertussis-like bacteria from ovine lungs. Microbiology 140(Pt 2), 255-261 (1994).
9. van der Zee A, Mooi F, Van Embden J, Musser J. Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. J. Bacteriol. 179(21), 6609-6617 (1997).
10. Parkhill J, Sebaihia M, Preston A et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nature Genet. 35(1), 32-40 (2003).
11. Finn TM, Stevens LA. Tracheal colonization factor: a Bordetella pertussis secreted virulence determinant. Mol. Microbiol. 16(4), 625-634 (1995).
12. Fernandez RC, Weiss AA. Serum resistance in bvg-regulated mutants of Bordetella pertussis. FEMS Microbiol Lett. 163(1), 57-63 (1998).
13. Caroff M, Aussel L, Zarrouk H et al. Structural variability and originality of the Bordetella endotoxins. J. Endotoxin. Res. 7(1), 63-68 (2001).
14. Allen AG, Thomas RM, Cadisch JT, Maskell DJ. Molecular and functional analysis of the lipopolysaccharide biosynthesis locus wlb from Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Mol. Microbiol. 29(1), 27-38 (1998).
15. Harvill ET, Preston A, Cotter PA, Allen AG, Maskell DJ, Miller JF. Multiple roles of Bordetella lipopolysaccharide molecules during respiratory tract infection. Infect. Immun. 68(12), 6720-6728 (2000).
16. Burns VC, Pishko EJ, Preston A, Maskell DJ, Harvill ET. Role of Bordetella O-antigen in respiratory tract infection. Infect. Immun. 71(1), 86-94 (2003).
17. Walker, E. Clinical aspects of pertussis. In: Pathogenesis and Immunity in Pertussis. Wardlaw, AC, Parton R (Eds). John Wiley & Sons Ltd, Chichester, UK, 273-282 (1988).
18. He Q, Arvilommi H, Viljanen MK, Mertsola J. Outcomes of Bordetella infections in vaccinated children: effects of bacterial number in the nasopharynx and patient age. Clin. Diagn. Lab. Immunol. 6(4), 534-536 (1999).
19. Mastrantonio P, Giuliano M, Stefanelli P et al. Bordetella parapertussis infections. Dev. Biol. Stand. 89, 255-259 (1997).
20. Mastrantonio P, Stefanelli P, Giuliano M et al. Bordetella parapertussis infection in children: epidemiology, clinical symptoms and molecular characteristics of isolates. J. Clin. Microbiol. 36(4), 999-1002 (1998).
21. Bergfors E, Trollfors B, Taranger J, Lagergard T, Sundh V, Zackrisson G. Parapertussis and pertussis: differences and similarities in incidence, clinical course and antibody responses. Int. Infect. Dis. 3(3), 140-156 (1999).
22. Weiss AA. The Genus Bordetella. In: The Prokaryote, Second Edition. Balows A, Truper HG, Dworkin M, Harder W, Schleifer KH (Eds). Springer New York, Inc. NY, USA (1992).
23. Hoppe JE. Methods for isolation of Bordetela pertussis from patients with whooping cough. Eur. J. Clin. Microbiol. Infect. Dis. 7, 616-620 (1988).
24. Aoyama T, Goto A, Iwai H et al. Simple and efficient method for clinical isolation of Bordetella pertussis. Dev. Biol. Stand. 73, 185-192 (1991).
25. Novotny P, Macaulay ME, Hart TC, Skvari F. Analysis of antibody profiles in children with whooping cough. Dev. Biol. Stand. 73, 267-273 (1991).
26. Wirsing von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis in adults and infants. Lancet Infect. Dis. 2(12), 744-750 (2002).
27. Preston NW. Pertussis (Whooping cough): the road to eradication is well sign-posted but eratically trodden. Infect. Dis. Rev. 2, 5-11 (2000).
28. Cloud JL, Hymas WC, Turlak A et al. Description of a multiplex Bordetella pertussis and Bordetella parapertussis LightCycler PCR assay with inhibition control. Diagn. Microbiol. Infect. Dis. 46(3), 189-195 (2003).
29. van der Zee A, Agterberg C, Peeters M, Mooi F, Schellekens J. A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. J. Infect. Dis. 174(1), 89-96 (1996).
30. Templeton KE, Scheltinga SA, Van Der Zee A et al. Evaluation of real-time PCR for detection of and discrimination between Bordetela pertussis, Bordetella parapertussis and Bordetella holmesii for clinical diagnosis. J. Clin. Microbiol. 41(9), 4121-4126 (2003).
31. Lind-Brandberg L, Welinder-Olsson C, Lagergard T, Taranger J, Trollfors B, Zackrisson G. Evaluation of PCR for diagnosis of Bordetella pertussis and Bordetella parapertussis infections. J. Clin. Microbiol. 36(3), 679-683 (1998).
32. Farrell DJ, Daggard G, Mukkur TK. Nested duplex PCR to detect Bordetella pertussis and Bordetella parapertussis and its application in diagnosis of pertussis in nonmetropolitan Southeast Queensland, Australia. J. Clin. Microbiol. 37(3), 606-610 (1999).
33. Borska K, Simkovicova M. Studies on the circulation of Bordetella pertussis and Bordetella parapertussis in populations of children. J. Hyg. Epidemiol. Microbiol. Immunol. 16(2), 159-172 (1972).
34. Khelef N, Danve B, Quentin-Millet MJ, Guiso N. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect. Immun. 61(2), 486-490 (1993).
35. David S, van Furth R, Mooi FR. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccines 22(15-16), 1892-1898 (2004).
36. Heininger U, Stehr K, Christenson P, Cherry JD. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clin. Infect. Dis. 28(3), 602-604 (1999).
37. de Melker HE, Schellekens JFP, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MAE. Re-emergence of pertussis in the highly vaccinated population of The Netherlands: observations on surveillance data. Emerg. Infect. Dis. 6(4), 348-357 (2000).
38. Mooi FR, van Loo IHM, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its re-emergence? Emerg. Infect. Dis. 7(3), 526-528 (2001).
39. Iwata S, Aoyama T, Goto A et al. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis in an apartment house. Dev. Biol. Stand. 73, 333-341 (1991).
40. Mertsola J. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis infection in Finland. Eur. J. Clin. Microbiol. 4(2), 123-128 (1985).
41. He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 280(7), 635-637 (1998).
42. Watanabe M, Nagai M. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection. Infect. Immun. 69(11), 6981-6986 (2001).
43. Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16(20), 2039-2046 (1998).
44. Mills KH, Barnard A, Watkins J, Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61(2), 399-410 (1993).
45. Redhead K, Watkins J, Barnard A, Mills KH. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 61(8), 3190-3198 (1993).
46. Watanabe M, Nagai M. Role of systemic and mucosal immune responses in reciprocal protection against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection. Infect. Immun. 71(2), 733-738 (2003).
47. van den Akker WM. The filamentous hemagglutinin of Bordetella parapertussis is the major adhesin in the phase-dependent interaction with NCI-H292 human lung epithelial cells. Biochem. Biophys. Res. Commun. 252(1), 128-133 (1998).
48. Lautrop H. Epidemics of parapertussis. 20 years' observations in Denmark. Lancet 1(7711), 1195-1198 (1971).
49. Stehr K, Cherry JD, Heininger U et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 101 (1 Pt 1), 1-11 (1998).
50. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J. Clin. Microbiol. 39(12), 4396-4403 (2001).
51. Kourova N, Caro V, Weber C et al. Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains. J. Clin. Microbiol. 41(8), 3706-3711 (2003).